rtPA recombinant tissue plasminogen activation
rtPA
tPA can be manufactured using recombinant biotechnology techniques; tPA produced by such means are referred to as recombinant tissue plasminogen activator (rtPA). Specific rtPAs include alteplase, reteplase, and tenecteplase. They are used in clinical medicine to treat embolic or thrombotic stroke. The use of this protein is contraindicated in hemorrhagic stroke and head trauma. The antidote for tPA in case of toxicity is aminocaproic acid.
Caranya:
100 mgr terbagi dalam
1. 50 mgr bolus IV
2. 20 mgr bolus IV pada jam ke-2
3. 30 mgr bolus IV pada jam ke-3
atau alternatif
1. 60 mgr bolus IV
2. 20 mgr bolus IV
3. 20 mgr bolus IV
https://www.researchgate.net/publication/8358453_The_Neurotoxicity_of_Tissue_Plasminogen_Activator/figures?lo=1
http://americanhistory.si.edu/collections/search/object/nmah_1000953
tPA can be manufactured using recombinant biotechnology techniques; tPA produced by such means are referred to as recombinant tissue plasminogen activator (rtPA). Specific rtPAs include alteplase, reteplase, and tenecteplase. They are used in clinical medicine to treat embolic or thrombotic stroke. The use of this protein is contraindicated in hemorrhagic stroke and head trauma. The antidote for tPA in case of toxicity is aminocaproic acid.
Caranya:
100 mgr terbagi dalam
1. 50 mgr bolus IV
2. 20 mgr bolus IV pada jam ke-2
3. 30 mgr bolus IV pada jam ke-3
atau alternatif
1. 60 mgr bolus IV
2. 20 mgr bolus IV
3. 20 mgr bolus IV
https://www.researchgate.net/publication/8358453_The_Neurotoxicity_of_Tissue_Plasminogen_Activator/figures?lo=1
http://americanhistory.si.edu/collections/search/object/nmah_1000953
Komentar
Posting Komentar